Emerging Biosensing Methods to Monitor Lung Cancer Biomarkers in Biological Samples: A Comprehensive Review

Abstract

Lung cancer is the most commonly diagnosed of all cancers and one of the leading causes of cancer deaths among men and women worldwide, causing 1.5 million deaths every year. Despite developments in cancer treatment technologies and new pharmaceutical products, high mortality and morbidity remain major challenges for researchers. More than 75% of lung cancer patients are diagnosed in advanced stages, leading to poor prognosis. Lung cancer is a multistep process associated with genetic and epigenetic abnormalities. Rapid, accurate, precise, and reliable detection of lung cancer biomarkers in biological fluids is essential for risk assessment for a given individual and mortality reduction. Traditional diagnostic tools are not sensitive enough to detect and diagnose lung cancer in the early stages. Therefore, the development of novel bioanalytical methods for early-stage screening and diagnosis is extremely important. Recently, biosensors have gained tremendous attention as an alternative to conventional methods because of their robustness, high sensitivity, inexpensiveness, and easy handling and deployment in point-of-care testing. This review provides an overview of the conventional methods currently used for lung cancer screening, classification, diagnosis, and prognosis, providing updates on research and developments in biosensor technology for the detection of lung cancer biomarkers in biological samples. Finally, it comments on recent advances and potential future challenges in the field of biosensors in the context of lung cancer diagnosis and point-of-care applications.

A comprehensive review on the biomedical frontiers of nanowire applications

“…In many circumstances, chemotherapy has little potential despite being the most widely used cancer therapy approach. oral or intravenous administration of drugs is the conventional method of chemotherapeutic medications so that only a portion of the dosage reaches the tumor site and the medication is distributed throughout the body [ 579 ] Approximately 1.5 million people worldwide lose their lives to lung cancer each year, making it the most frequently diagnosed cancer overall and one of the main causes of cancer-related fatalities in both men and women [ 580 ].…”

Biosensing of Alpha-Fetoprotein: A Key Direction toward the Early Detection and Management of Hepatocellular Carcinoma

“…Researchers have focused mainly on enhancing the limit of detection (LOD), time-dependent sensitivity, and selectivity of the target analyte. So, efforts are directed at improving the affinity of recognition surfaces to biomarkers, using advanced fabrication strategies, modifying surface chemicals, and incorporating nanomaterials [36][37][38][39].…”

Low-Cost Point-of-Care Monitoring of ALT and AST Is Promising for Faster Decision Making and Diagnosis of Acute Liver Injury

“…Therefore, there is great anticipation from researchers to develop simple, cheap, and easy-to-use point-of-care (POC) diagnostic tools to diagnose and monitor patients’ health status. Several research groups have reported strategies for POC diagnosis by detecting metabolites and proteins using paper, thread, and magnetic levitation [ 15 , 16 , 17 , 18 ]. In addition, inexpensive colorimetric enzyme-linked immunosorbent assays (ELISAs) using paper have also been developed to detect antibodies in biological fluids [ 19 ].…”